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Investigation performed at Durham University, Stockton, United Kingdom
Background: More than 75,000 total hip replacements were performed in England and Wales in 2014, and this ﬁgure
is predicted to increase. Trends in mortality and complications following total hip replacement from 2005 to 2014 were
evaluated to quantify risk and to identify “at-risk” groups to better inform recommendations for patient care.
Methods: Our primary analysis estimated 90-day inpatient mortality following total hip replacement using Hospital Episode
Statistics data from 2005 to 2014. Secondary analyses explored 30-day rates of lower respiratory tract infection, renal
failure, myocardial infarction, pulmonary embolism, deep-vein thrombosis, cerebrovascular accident, and Clostridium difﬁ-
cile.Hierarchical logistic regression was used to estimate population averages, adjusting for time and prognostic covariates.
Results: From January 2005 to July 2014, a total of 540,623 total hip replacements were reported. The 90-day mortality
rate dropped steadily, from 0.60% in 2005 to 0.15% in 2014. Reported postoperative complications (with the exception of
lower respiratory tract infection and renal failure) reduced year-on-year, despite a steady rise in the average Charlson
Comorbidity Index score. The 30-day rate of lower respiratory tract infection and renal failure increased from 0.54% to
0.84% and 0.21% to 1.09%, respectively. The risk of mortality was signiﬁcantly higher for those who developed a lower
respiratory tract infection (odds ratio [OR] = 42.3) or renal failure (OR = 36.5) than for those who developed pulmonary
embolism (OR = 10.9) or deep-vein thrombosis (OR = 2.6).
Conclusions: Despite a population with increasing levels of comorbidity, indicators of quality of care improved from
2005 to 2014, with the exception of the rates of lower respiratory tract infection and renal failure. Postoperative care
should focus on reducing the risk of lower respiratory tract infection and renal failure, both of which increased and were
strongly associated with mortality. Moreover, they appeared to occur in identiﬁable high-risk groups; modiﬁcations to
routine care should be considered for these patients.
Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
T
otal hip replacement is a highly successful and cost-
effective intervention, with >75,000 procedures
performed in England and Wales in 20141-3. Compre-
hensive data from the National Joint Registry for England,
Wales, and Northern Ireland (NJR) have permitted detailed
understanding of how and why the performance of hip
replacement surgery varies and the inﬂuences on surgical and
patient outcomes of a range of surgical, patient, and prosthesis
characteristics4. The publication of surgeon-level data was in-
troduced in England and Wales in June 2013 to increase
Disclosure: No external funding was received for this study. TheDisclosure of Potential Conﬂicts of Interest forms are provided with the online version of
the article (http://links.lww.com/JBJS/E620).
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TABLE I Demographics of Patients Who Underwent Total Hip Replacement (THR) from January 2005 to July 2014*
2005 2014 Overall
% 95% CI % 95% CI P Value %
No. of THRs 34,643 40,758 540,623
Sex
No. of female 21,359 61.7 61.1-62.1 24,469 60.0 59.6-60.6 <0.0001 328,941 60.8
No. of male 13,249 38.2 37.9-38.9 16,282 39.9 39.4-40.4 <0.0001 211,280 39.1
No. unknown 35 0.1 7 0.01 402 0.1
Mean age (yr)
Overall 69.0 68.8-69.7 68.0 67.9-68.1 <0.0001 68.4
Female 69.8 69.7-69.9 68.8 68.6-68.9 <0.0001 69.2
Male 67.6 67.4-67.8 66.7 66.6-66.9 <0.0001 67.1
No. with
comorbidities
No
comorbidities
21,445 61.9 61.4-62.4 19,338 47.4 47.0-47.9 <0.0001 283,428 52.4
Hypertension 10,727 31.0 30.5-31.5 18,374 45.1 44.6-45.6 <0.0001 216,283 40.0
IHD 1,854 5.4 5.1-5.6 2,868 7.0 6.8-7.3 <0.0001 35,593 6.6
AF 1,423 4.1 3.9-4.3 2,392 5.9 5.6-6.1 <0.0001 28,288 5.2
IDDM 156 0.5 0.4-0.5 133 0.3 0.3-0.4 0.006 2,132 0.4
NIDDM 1,995 5.8 5.5-6.0 3,704 9.1 8.8-9.4 <0.0001 42,970 7.9
COPD 691 2.0 1.8-2.1 1,737 4.3 4.1-4.5 <0.0001 17,349 3.2
*CI = conﬁdence interval, IHD = ischemic heart disease, AF = atrial ﬁbrillation, IDDM = insulin-dependent diabetes mellitus, NIDDM = non-insulin-dependent diabetes
mellitus, and COPD = chronic obstructive pulmonary disease.
Fig. 1
Annual 90-day inpatient mortality rate following primary total hip replacement among NHS patients in England. The error bars indicate the 95% conﬁdence
interval.
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transparency regarding surgical outcomes5. The information
published includes surgeon volume and 90-day mortality. At the
national level, the associated 90-day mortality rate after a hip
replacement fell consistently in recent years, from 0.56% in 2003
to 0.29% in 20116. Major complications have been noted to occur
in 2% of procedures7, with the majority occurring in the ﬁrst 4
postoperative days8.
Experiencing a major complication is associated with a
higher mortality rate9,10. However, low rates of complications
make it difﬁcult to determine risk factors from case-series re-
ports. The Hospital Episode Statistics (HES) data warehouse
provides access to inpatient data on all joint replacements per-
formed in the English National Health Service (NHS). Novel
methods of analyzing these data can provide clinicians with new
insights into the best ways to treat individual patients, by tailoring
perioperative and postoperative care. This has the potential to
reduce morbidity and mortality, reduce health-care costs, and
maximize the beneﬁt of total hip replacement. It should also
allow improved “patient-speciﬁc” informed consent and provide
evidence to redirect valuable health-care resources to more ap-
propriate “at-risk” groups.
To our knowledge, there are currently no validated risk tools
for reliably estimating complications after total hip replacement.
The American College of Surgeons National Surgical Quality
Improvement Program (ACS NSQIP) surgical risk calculator11
was developed in 2013 from >1.4million cases but fails to provide
accurate risk estimations for lower-limb joint replacement12. At-
tempts to make arthroplasty-speciﬁc tools have objectively been
underpowered and require external validation13. By analyzing
complication rates over time, we aimedwith this study to provide
current risk estimations on the basis of a large cohort of patients,
to inform recommendations for the care of high-risk groups.
Materials and Methods
Our research was limited to the secondary use of non-identiﬁable information previously collected in the course
of normal care and was therefore exempt from formal ethical
approval.
Study Design and Data
This was a retrospective cohort study. We used HES data to
assess rates, trends, and determinants of complications
among all patients who underwent NHS-funded primary
total hip replacement in England from January 2005 to July
2014. For patients who underwent >1 joint replacement
during the study period, each replacement was treated as a
discrete event.
HES data in the form of the OPCS-4 (Ofﬁce of Popu-
lation Censuses and Surveys Classiﬁcation of Surgical Oper-
ations and Procedures, 4th Revision) and ICD-10
(International Statistical Classiﬁcation of Diseases and
Related Health Problems, 10th Revision) codes were used to
establish rates of myocardial infarction, cerebrovascular ac-
cident, lower respiratory tract infection, renal failure, deep-
vein thrombosis, pulmonary embolism, and Clostridium
difﬁcile infection within 30 days (see Appendix). All-cause
inpatient 90-day mortality was also extracted. Age, sex, co-
morbidities, and Charlson Comorbidity Index (CCI) score14
were recorded for each patient. The CCI predicts patient
1-year mortality.
Statistical Methods
The analytic framework was hypothesis-generating rather
than formal hypothesis-testing, and thus, a p value of <0.05 was
considered signiﬁcant for ﬁndings meriting further investiga-
tion, without adjustment for multiple comparisons.
The primary analysis estimated 90-day inpatient mor-
tality following hip replacement. Event rates over time were
explored using a hierarchical logistic model, with hospital
trust as a random effect, and estimating population average
estimates, averaging trust-level random effects, and providing
robust standard errors. Serial autocorrelation was explored
and excluded from the ﬁnal models as insigniﬁcant to the
estimation. Model covariates explored at the patient level were
age, sex, and history of hypertension, atrial ﬁbrillation, is-
chemic heart disease, hyperthyroidism, hypothyroidism,
insulin-dependent diabetes mellitus, non-insulin-dependent
diabetes mellitus, circulatory disease, chronic obstructive
pulmonary disease (COPD), dementia, Alzheimer disease,
and osteoporosis. Secondary analyses similarly explored
30-day rates of other events: myocardial infarction, cerebro-
vascular accident, lower respiratory tract infection, renal
failure, deep-vein thrombosis, pulmonary embolism, and
C. difﬁcile.
Analyses were performed using STATA/IC (version
13.1; StataCorp); proportions were estimated from models
using reported odds and odds ratios (ORs). Model esti-
mates were used to plot ﬁtted lines by population and
subpopulation.
Patient Involvement
No patients were involved in setting the research question or
the outcome measures. In tandem with this project, a quali-
tative study will explore the patient experience of complica-
tions as well as the consenting process. The end goal is to
Fig. 2
Annual distribution of Charlson Comorbidity Index scores.
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enhance shared decision-making, the patient experience, and
outcomes.
Results
From January 2005 to July 2014, a total of 540,623 total hipreplacements (474,128 patients) were recorded in HES. Of
those hip replacements, 328,941 (60.8%) were performed in
female patients, with a mean age of 69.2 years, and 211,280
(39.1%) were performed in male patients, with a mean age of
67.1 years. The frequency of recorded comorbidities is shown
in Table I.
The 90-day mortality rate consistently dropped an-
nually, from 0.60% in 2005 to 0.15% in 2014 (p < 0.0001)
(Fig. 1). This was despite a progressive increase in the levels
of comorbidity, as shown by the CCI score distribution
(Fig. 2).
Postoperative complications, with the exception of
lower respiratory tract infection and renal failure, decreased
annually (Table II). The 30-day rate of myocardial infarction
decreased from 0.48% to 0.18% (p < 0.0001); pulmonary
embolism, from 0.77% to 0.40% (p < 0.0001); deep-vein
thrombosis, from 1.15% to 0.28% (p < 0.0001); and
C. difﬁcile, from 0.16% to 0.02% (p < 0.0001). The 30-day
rate of lower respiratory tract infection and renal failure
increased from 0.54% to 0.84% (p < 0.0001) and 0.21% to
1.09% (p < 0.0001), respectively, and were the most frequent
complications in 2014. The associated risk of 90-day inpa-
tient mortality was signiﬁcantly higher for those who
developed a lower respiratory tract infection (OR = 42.3;
95% conﬁdence interval [CI] = 37.6 to 47.5; p < 0.0001) or
renal failure (OR = 36.5; 95% CI = 32.1 to 41.6; p < 0.0001)
than for those who developed pulmonary embolism
(OR =10.9; 95% CI = 8.9 to 13.4; p < 0.0001) or deep-vein
thrombosis (OR = 2.6; 95% CI = 1.8 to 3.8; p < 0.0001). The
overall risks of mortality associated with these conditions all
decreased over the study period, with the exception of my-
ocardial infarction and C. difﬁcile.
After adjusting for age, sex, and comorbidities, we noted
an association between 90-day inpatient mortality and preex-
isting ischemic heart disease (OR = 2.3; 95%CI= 2.1 to 2.7; p <
0.001), atrial ﬁbrillation (OR = 2.5; 95% CI = 2.2 to 2.8; p <
0.001), insulin-dependent diabetes mellitus (OR = 2.8; 95%
CI = 1.7 to 4.5; p < 0.001), non-insulin-dependent diabetes
mellitus (OR = 1.4; 95% CI = 1.2 to 1.6; p < 0.001), and COPD
(OR = 2.8; 95% CI = 2.4 to 3.3; p < 0.001), but not hyper-
tension (OR = 0.9; 95% CI = 0.9 to 1.0; p = 0.265) (Table III).
The risk of experiencing postoperative myocardial in-
farction was associated with preexisting ischemic heart disease
(OR = 4.6; 95% CI = 4.0 to 5.2; p < 0.001), atrial ﬁbrillation
(OR = 2.1; 95% CI = 1.9 to 2.4; p < 0.001), and insulin-
dependent diabetes mellitus (OR = 2.3; 95%CI = 1.4 to 3.7; p <
0.001). The risk of developing a postoperative lower respiratory
tract infection was associated with a previous diagnosis of
COPD (OR = 3.1; 95% CI = 2.8 to 3.5; p < 0.001) or atrial
ﬁbrillation (OR = 2.4; 95% CI = 2.1 to 2.6; p < 0.001). The risk
of experiencing postoperative renal failure was strongly asso-
ciated with preexisting insulin-dependent diabetes mellitus
(OR = 5.0; 95% CI = 3.7 to 6.8; p < 0.001) and, to a lesser
extent, atrial ﬁbrillation (OR = 2.1; 95% CI = 1.9 to 2.3; p <
0.001), non-insulin-dependent diabetes mellitus (OR = 2.2;
95% CI = 2.0 to 2.4; p < 0.001), and COPD (OR = 2.0; 95%
CI = 1.7 to 2.2; p < 0.001).
TABLE II Associated Risk of 90-Day Mortality, by Complication, Following Total Hip Replacement from January 2005 to July 2014*
2005, N = 34,643 2014, N = 40,758 Overall, N = 540,623
No. (%)
90-Day Mortality
No. (%)
90-Day Mortality
No. (%)
90-Day Mortality
No. (%)† OR (95% CI) No. (%)† OR (95% CI) No. (%)† OR (95% CI)
MI 167 (0.48) 38 (22.8) 59.8
(40.4-88.5)
75 (0.18) 7 (9.33) 78.9
(34.6-179.8)
1,906 (0.35) 273 (14.3) 59.2
(51.6-67.9)
PE 268 (0.77) 18 (6.7) 13.0
(7.9-21.5)
162 (0.40) 2 (1.23) 8.7
(2.1-36.1)
2,967 (0.55) 99 (3.34) 10.9
(8.9-13.4)
DVT 400 (1.15) 5 (1.3) 2.1
(0.9-5.2)
116 (0.28) 0 — 3,376 (0.62) 29 (0.86) 2.6
(1.8-3.8)
CVA 2 (0.01) 0 — 6 (0.01) 2 (33.3) 350.8
(63-1,952.9)
61 (0.01) 18 (29.5) 127.3
(73-221.1)
RF 73 (0.21) 15 (20.5) 46.3
(25.8-83.1)
443 (1.09) 15 (3.39) 31.4
(17.4-56.7)
3,242 (0.60) 299 (9.22) 36.5
(32.1-41.6)
LRTI 188 (0.54) 34 (18.1) 43.8
(29.3-65.3)
342 (0.84) 14 (4.09) 37.5
(20.4-68.8)
3,907 (0.72) 389 (9.96) 42.3
(37.6-47.5)
C. difﬁcile 57 (0.16) 12 (21.1) 47.0
(24.5-90.2)
8 (0.02) 1 (12.5) 98.5
(11.9-813.3)
510 (0.09) 68 (13.3) 48.1
(37.1-62.4)
*OR = odds ratio, CI = conﬁdence interval, MI = myocardial infarction, PE = pulmonary embolism, DVT = deep-vein thrombosis, CVA = cerebrovascular accident, RF =
renal failure, LRTI = lower respiratory tract infection, and C. difﬁcile = Clostridium difﬁcile.†The percentage is of the total number of hip replacements with the indicated
complication at that time period.
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Discussion
Despite a population with increasing levels of comorbidity,indicators of quality of care improved from 2005 to 2014,
with the exception of the rates of lower respiratory tract infection
and renal failure. Perioperative complication and mortality rates
are key concerns for patients, anesthetists, and surgeons. Elective
hip arthroplasty is consistently reported to have a very low peri-
operative mortality rate15-22 and lowmedical complication rates8,22.
However, Dimick et al. concluded that the minimum caseload
necessary to detect a doubling of the mortality rate for hip re-
placement surgery was 2,668 cases23. In order to reliably identify
changes in mortality or medical complications, single institutions
need to collect data over large time intervals to accumulate data
that demonstrate signiﬁcance24. The average number of total hip
replacements performed per unit was 363 in England in 2013,
inferring that >7 years of data are required to attain the estimation
of Dimick et al. This carries the risk of averaging results over
decades despite notable improvements in the quality of care over
time. In contrast, large regional or national databases in Europe
and the U.S. provide more statistically robust data, allow earlier
detection of potential problems, and eliminate single institution-
based selection bias8,25-27.
TABLE III Odds Ratios (and 95% CIs) for Complications and 90-Day Mortality, by Comorbidity*
Complication
Comorbidity MI PE DVT CVA RF LRTI C. difﬁcile
90-Day
Mortality
HTN 2005 1.2
(0.8-1.6)
0.9
(0.7-1.1)
1.0
(0.8-1.3)
— 2.0
(1.3-3.3)†
1.2
(0.9-1.7)
0.8
(0.4-1.4)
1.0
(0.8-1.4)
2014 1.2
(0.7-2.0)
1.0
(0.7-1.4)
0.7
(0.5-1.1)
0.7
(0.1-3.6)
1.6
(1.3-1.9)‡
0.9
(0.7-1.2)
0.7
(0.2-3.2)
1.5
(0.8-2.6)
Overall 1.2
(1.1-1.3)‡
1.0
(0.9-1.1)
1.0
(0.9-1.1)
0.7
(0.4-1.3)
1.3
(1.2-1.4)‡
1.0
(0.9-1.1)
0.8
(0.7-1.0)
0.9
(0.9-1.0)
IHD 2005 5.9
(4.3-8.3)‡
1.6
(1.0-2.4)†
0.8
(0.5-1.2)
— 1.2
(0.6-2.5)
2.4
(1.6-3.5)‡
3.0
(1.4-6.4)†
2.7
(1.9-3.8)‡
2014 9.0
(5.6-14)‡
1.2
(0.7-2.0)
0.9
(0.4-1.9)
3.2
(0.5-19)
1.5
(1.1-1.9)†
1.7
(1.3-2.3)‡
0.7
(0.1-9.1)
2.1
(1.1-3.8)†
Overall 4.6
(4.0-5.2)‡
1.3
(1.2-1.5)‡
1.1
(0.9-1.2)
1.1
(0.5-2.5)
1.6
(1.5-1.8)‡
1.6
(1.4-1.7)‡
1.4
(1.0-1.8)†
2.3
(2.1-2.7)‡
AF 2005 3.2
(2.2-4.7)‡
1.7
(1.1-2.7)†
0.8
(0.5-1.4)
— 2.7
(1.5-5.1)†
3.1
(2.1-4.6)‡
2.0
(0.9-4.5)
2.5
(1.7-3.6)‡
2014 2.3
(1.3-4.0)†
1.1
(0.6-1.9)
1.7
(0.9-3.3)
4.6
(0.8-27)
2.1
(1.6-2.6)‡
2.5
(1.9-3.4)‡
1.0
(0.1-12.0)
2.6
(1.4-4.7)†
Overall 2.1
(1.9-2.4)‡
1.4
(1.3-1.6)‡
1.0
(0.9-1.2)
1.9
(0.8-4.2)
2.1
(1.9-2.3)‡
2.4
(2.1-2.6)‡
2.0
(1.6-2.6)‡
2.5
(2.2-2.8)‡
IDDM 2005 1.2
(0.2-8.5)
2.3
(0.7-7.3)
— — 3.0
(0.4-22)
— — —
2014 6.8
(1.6-29)†
1.8
(0.3-13)
— — 5.9
(2.8-12)‡
0.8
(0.1-5.8)
40
(3.3-494)‡
4.1
(0.5-31)
Overall 2.3
(1.4-3.7)‡
0.8
(0.4-1.4)
0.7
(0.4-1.4)
1.0
(1.0-1.0)
5.0
(3.7-6.8)‡
1.6
(1.1-2.5)†
1.0
(0.2-4.0)
2.8
(1.7-4.5)‡
NIDDM 2005 1.8
(1.2-2.9)†
0.5
(0.2-0.9)†
1.0
(0.6-1.5)
— 2.3
(1.3-4.4)†
1.7
(1.1-2.7)‡
0.5
(0.1-2.1)
0.7
(0.4-1.3)
2014 1.2
(0.6-2.2)
1.2
(0.7-1.9)
1.3
(0.7-2.4)
— 2.4
(1.9-3.0)‡
1.4
(1.0-1.8)†
3.5
(0.6-19)
1.0
(0.5-2.1)
Overall 1.7
(1.5-1.9)‡
0.8
(0.7-1.0)†
1.0
(0.8-1.1)
1.1
(0.5-2.6)
2.2
(2.0-2.4)‡
1.3
(1.2-1.4)‡
1.2
(0.9-1.6)
1.4
(1.2-1.6)‡
COPD 2005 0.8
(0.3-2.1)
1.6
(0.9-3.1)
1.0
(0.5-2.0)
— 3.2
(1.4-7.6)†
2.9
(1.6-5.1)‡
— 2.3
(1.3-4.1)†
2014 1.1
(0.5-2.5)
2.3
(1.4-3.9)†
1.6
(0.8-3.2)
— 1.8
(1.3-2.4)‡
3.5
(2.6-4.7)‡
— 3.0
(1.5-6.1)†
Overall 1.4
(1.1-1.6)†
1.5
(1.3-1.8)‡
1.4
(1.2-1.6)‡
1.2
(0.4-3.6)
2.0
(1.7-2.2)‡
3.1
(2.8-3.5)‡
2.3
(1.7-3.2)‡
2.8
(2.4-3.3)‡
*After adjustment for age, sex, and other comorbidities. CI = conﬁdence interval, MI = myocardial infarction, PE = pulmonary embolism, DVT = deep-vein thrombosis,
CVA = cerebrovascular accident, RF = renal failure, LRTI = lower respiratory tract infection, C. difﬁcile = Clostridium difﬁcile, HTN = hypertension, IHD = ischemic heart
disease, AF = atrial ﬁbrillation, IDDM = insulin-dependent diabetes mellitus, NIDDM = non-insulin-dependent diabetes mellitus, and COPD = chronic obstructive
pulmonary disease. †P < 0.05. ‡P < 0.001.
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The aim of this study was to determine up-to-date
medical complication and mortality rates, identifying “at-risk”
groups following hip arthroplasty in England. Our national
data analysis showed an annual reduction in the 90-day mor-
tality rate after total hip replacement consistent with, and
extending, a recent NJR analysis6. It is generally accepted that
the risk of mortality is highest immediately following surgery,
but the overall 90-day mortality rate was lower than that pre-
viously reported for age, sex and comorbidity-matched pa-
tients who did not undergo total hip replacement27,28.
The publication of surgeon-level data introduced in 2013
has sharpened focus on complications after surgery, with the
intention of increasing transparency and, ultimately, reducing
mortality5. The consistent drop in mortality after total hip re-
placement during the period of study implies successive ad-
vances in surgical practice and medical care, irrespective of the
publication of surgeon-level outcome data.
Although our HES data did not include privately funded
patients, we know that 88% of hip replacements in England in
2014 were performed within the NHS3. Evidence suggests that
private institutions tend to “cherry-pick” the healthier patients
(limited critical care provision in the private sector precludes
patients of higher surgical risk), and we would therefore expect
that our data would over-represent the complication and
mortality rates compared with data including those of patients
in the private sector29. Our current study also included NHS
patients at private units and independent treatment centers.
A potential limitation of our study was the quality of HES
data. The database relies on the precision of trained but non-
medical staff inputting data using the ICD-10 and OPCS-4
coding systems. As these patients were planned admissions for
surgery, it was assumed that none of the complications oc-
curred prior to total hip replacement. HES is an internationally
unique resource, the accuracy of which is perceived to be im-
proving since the introduction of payment by results in 2004.
As these data are used for billing, each trust is externally au-
dited. A recent audit of 50 trusts found an average error rate
of 7.0%30.
HES data also have the limitation of the recording of only
inpatient deaths. The data set captures readmission with sub-
sequent death but does not record deaths occurring outside the
hospital. Therefore, the absolute mortality rate is under-
estimated. Our mortality trend is, however, consistent with that
of a previous national study that used Ofﬁce of National Sta-
tistics data to identify all deaths6.
For patients who underwent >1 joint replacement during
the 10-year study period, each replacement was treated as a
discrete event. Having a previous hip replacement could impact
future risk and, therefore, overall complication estimates.
However, it was not possible to exclude all patients who had
had a hip replacement prior to 2005 or any other surgical
procedure during the period of study.
The CCI14 is a widely used tool and has demonstrated
excellent predictive validity31. However, this index tends to
underestimate comorbidity because it is limited to 19 condi-
tions and has poor interconditional weighting, but its simplicity
in design makes its adaptation feasible31. The apparent increase
in annual CCI scores may be a result of improved coding;
however, one would also expect a similar increase in codes for
complications such as deep-vein thrombosis and pulmonary
embolism. The improved diagnosis of many conditions such as
hypertension and non-insulin-dependent diabetes mellitus is
known to have increased with time32.
HES data do not include speciﬁc cause of death. A pre-
vious report15 found that the main cause of death following
total hip replacement was cardiovascular-related. Our study
found lower respiratory tract infection to be the complication
most commonly associated with death following joint re-
placement. The lower respiratory tract infection rate was 0.72%
(3,907 procedures), with mortality reported following 389
(9.96%) of those procedures. Renal failure was the second-
most common complication associated with mortality. The
renal failure rate was 0.60%, with mortality reported following
299 (9.22%) of 3,242 procedures. However, renal failure is
more likely to be simultaneous with other complications and,
therefore, may not have been the main cause of death; HES data
do not classify severity of kidney injury. The myocardial in-
farction rate in our study was 0.35%, with mortality reported
following 273 (14.3%) of 1,906 procedures. This did not,
however, take into consideration the possibility of silent myo-
cardial infarction33.
Pulmonary embolism following arthroplasty remains a
much-debated topic, particularly with regard to choices of
thromboprophylaxis34-36. In scrutinizing the records of all pa-
tients following primary hip replacement in 1990 in a single
U.K. health region, Fender et al. found a fatal pulmonary
embolism rate of 0.19% (4 of 2,090 patients) and determined
that a study would require 67,000 randomized patients to be
signiﬁcant if fatal pulmonary embolism were to be used as the
end point37. Wroblewski et al. showed 122 pulmonary
embolism-related deaths in 18,104 Charnley arthroplasties
(0.67%) from 1970 to 198638, and Lie et al. found a fatal pul-
monary embolism rate of 0.92% between 1987 and 1995
(45,767 patients)16. Our data revealed a pulmonary embolism
rate of 0.55%, and a fatal pulmonary embolism rate of only
0.018% (99 total hip replacements). The consistent reduction
in both pulmonary embolism and deep-vein thrombosis could
be attributed to adherence to National Institute of Clinical
Excellence (NICE) guidance on venous thromboembolism
(VTE) prophylaxis. However, the adherence to and effect of
VTE guidance has previously been questioned34 and the ob-
served reductions in deep-vein thrombosis and pulmonary
embolism rates may be the result of enhanced recovery pro-
tocols, including the switch from general to spinal anesthesia
and early postoperative mobilization. The implementation of
such protocols has been shown to reduce short-term compli-
cations and mortality39.
Three times as many patients died following lower res-
piratory tract infection as compared with pulmonary embo-
lism, yet no routine prophylaxis is provided to reduce the risk
of respiratory-related complications. Preoperative respiratory
physiotherapy has been associated with a reduction in
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postoperative pulmonary complications in cardiac and major
abdominal surgery40. Its role in lower-limb joint arthroplasty,
to our knowledge, has not been described, but it could be
adopted for at-risk patients, such as those with COPD.
All indicators of quality of care improved from 2005 to
2014, with the exception of the rates of lower respiratory tract
infection and renal failure. We hypothesize that the increased
rate of renal failure may be as a result of the national drive to
reduce C. difﬁcile by promoting a change in surgical prophy-
laxis from cephalosporins to gentamicin, while acknowledging
that nationwide practice remains varied41. Gentamicin is as-
sociated with an increased rate of renal failure even when used
as a single-dose prophylaxis42. The rate of C. difﬁcile fell, from
0.16% to 0.02% (in line with C. difﬁcile rates generally in
England)43, but potentially at the expense of increasing renal
failure. For at-risk patients (notably, patients with diabetes),
alternatives to gentamicin could be considered for surgical
prophylaxis. The ﬁndings of a recent large randomized trial
suggest that statins may increase rates of renal failure after
surgery44. While acknowledging their potential beneﬁt in re-
ducing the risk of ischemia in patients undergoing cardiac
surgery, we should consider stopping the use of statins in total
hip replacement patients at high risk of renal failure.
Total joint replacement in the English NHS has a very low
risk of mortality and postoperative complications: 3% of pro-
cedures being followed by a medical complication. Despite a
population with progressively more comorbidities, the rates of
complications, with the exception of those of lower respiratory
tract infection and renal failure, improved from 2005 to 2014.
To date, the drive for quality has focused on avoiding deep-vein
thrombosis and pulmonary embolism. This should now focus
on chest infections and renal failure, which were more com-
mon, increased, and very strongly associated with death.
Identifying at-risk groups for additional prophylactic measures
could reduce these complications.
Appendix
A table showing the ICD-10 and OPCS-4 codes used in our
analysis is available with the online version of this article as a
data supplement at jbjs.org (http://links.lww.com/JBJS/E621). n
NOTE: The authors thank Philip James of Caspe Healthcare Knowledge Systems (CHKS) for his
support and contribution. CHKS provided data and advice on clinical coding to support this study
(free of charge) in order to assist in furthering the understanding of outcomes in English NHS
hospitals. HES data were reused with permission of the Health and Social Care Information Centre.
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